|
Disease | Cells analyzed | | Study groups | MN | Year/reference |
Basal | Posttreatment |
|
Organ specific autoimmune diseases |
|
Graves’ disease (GD)
| Ly 2000 cells | 11 | GD + vit. E, after 131I | 4.0 ± 3.2 | 10.3 ± 1.7 (7 d)c 13.7 ± 2.3 (21 d) 3.9 ± 2.2 (180 d) | 2004 [18] |
Ly 2000 cells | 15 | GD + placebo after 131I | 5.2 ± 1.0 | 12.5 ± 1.6 (7 d) 24.7 ± 3.6 (21 d)c |
2007 [19] |
10 | GD + Ginkgo biloba after 131I | 8.7 ± 1.8 | 14.3 ± 2.2 (7 d) 12.4 ± 1.9 (21 d)
|
Ly NA | 25 25 | GD 7 days after 131I GD 30 days after 131I | NA NA | 2.4 ± 1.4% 1.9 ± 0.2%a | 2011 [20] |
|
Diabetes mellitus (DM)
| BM 2000 cells | 55 23 30 81 | T1DM T2DM DM + folic acid Healthy subjects | 2.4 ± 1.4b 2.6 ± 1.6 2.5 ± 1.4 1.2 ± 1.2 | 0.7 ± 0.6c (30 d) | 2007 [21] |
Ly 2000 cells | 35 15 | T1DM Healthy subjects | 1.8 ± 1.2 1.5 ± 0.6 | | 2009 [22] |
|
Multiple sclerosis (MS)
| Ly 1000 cells | 23 20 | MS + radiation Healthy subjects | 45.3 ± 3.3 27 ± 3.5 | 381 ± 16a 347 ± 13 | 2006 [23] |
Ly 1000 cells | 18 18 20 | RRMS + radiation SPMS + radiation Healthy subjects + radiation | 14.2 ± 6.1 12.7 ± 4.4 15.2 ± 6.5 | 86.0 ± 15.9a 86.6 ± 22.8a 96.7 ± 19.4a | 2013 [24] |
|
Vitiligo | Ly 1000 cells | 21 21 | Vitiligo without treatment Healthy subjects | 0.9 ± 0.6%a 0.6 ± 0.3% | | 2008 [25] |
|
Psoriasis | Ly 1000 cells | 5 6 5 5 | P + acitretin (oral) alone P + acitretin + NBUVB Acitretin + PUVA Healthy subjects | NA NA NA NA | NS NS a NA | 2013 [26] |
|
Systemic autoimmune diseases |
|
Rheumatoid arthritis (RA)
| BM 2000 cells | 29 50 40 39 | RA without MTX RA with MTX RA + MTX + folic acid Healthy subjects | 3.5 ± 1.5 3.1 ± 3.1 3.1 ± 2.9 0.8 ± 0.8 | 3.1 ± 2.8 | 2002 [12] |
Ly 1000 cells | 12 31 30 | Active RA Inactive RA Healthy subjects | 3.3 ± 1.3a 3.2 ± 1.1a 1.9 ± 1.1 | | 2011 [27] |
|
Systemic lupus erythematosus (SLE)
| Ly 2000 cells | NA | SLE without treatment SLE with CYC Healthy subjects | 6.2 ± 2.4 10.1 ± 4.7c 5.5 ± 2.2 | | 1995 [28] |
Ly 2000 cells | 15 18 | SLE without treatment Healthy subjects | 10.6 ± 3.9% 9.1 ± 4.6% | | 1999 [4] |
BM 1000 cells | 10 10 7 7 43 | SLE before first CYC bolus SLE 14 days after 1st CYC bolus SLE before second CYC bolus SLE 14 after the 2nd CYC bolus Healthy subjects | NA | 1.5 ± 1.6 2.9 ± 2.1 4.5 ± 2.3a 7.0 ± 2.8b 1.3 ± 1.3 | 2000 [13] |
BM 1000 cells | 25 24 43 | SLE without CYC SLE with CYC Healthy subjects | 0.9 ± 1.1 1.3 ± 1.2 1.3 ± 1.4 | 3.4 ± 2.2 (14 d)c | 2004 [29] |
BM 1000 cells | 58 58 | SLE patients Healthy controls |
Median cell counts of MN were significantly higher among SLE patients | 2014 [30] |
|
Systemic sclerosis (SSc)
| Ly 2000 cells | 11 5 6 18 | SSc SSc (ACA+/Scl70−) SSc (ACA−/Scl70+) Healthy subjects | 27.4 ± 19.9b 38.0 ± 24.9b 18.7 ± 9.5b 9.1 ± 4.6 | | 1999 [4] |
Ly 1000 cells | 43 13 16 25 | SSc Idiopathic RP Secondary RP Healthy subjects | 19.1 ± 2.1 23.5 ± 2.7 9.4 ± 2.2 25.9 ± 1.7 | | 2003 [31] |
Fibroblasts 1000 | 10 10 9 | SSc (nonaffected skin) + bleomycin SSc (affected skin) + bleomycin Healthy subjects + bleomycin | 15.4 ± 13.6 14.0 ± 12.0 4.7 ± 3.3 | 38.5 ± 17.9a 38.0 ± 26.1a 20.5 ± 13.1 | 2010 [32] |
|
Behçet’s disease (BD)
| BM 1000 cells | 10 6 4 9 | Patients with BD BD treated with colchicine BD without colchicines Healthy subjects | 1.9 ± 0.9 1.7 ± 1.0 2.3 ± 0.5 0.8 ± 0.7 | | 2005 [33] |
Ly 1000 cells | 30 10 20 20 | Patients with BD BD without colchicine BD with colchicine Healthy subjects | 3.4 ± 1.1 3.6 ± 1.2a 3.4 ± 1.1a 2.2 ± 0.7 | |
Ly 1000 cells | 14 16 20 | BD inactive BD active Healthy subjects | 3.1 ± 1.3b 3.2 ± 1.2a 2.2 ± 0.7 | | 2009 [34] |
Ly 1000 cells | 18 22 30 | BD negative HLA-B51 BD positive HLA-B51 Healthy subjects | 2.6 ± 0.7c 3.5 ± 0.7c 1.7 ± 0.3 | | 2013 [35] |
|